Uceris

Budesonide

Clinical data
Trade names	Pulmicort, Rhinocort, others
AHFS/Drugs.com	Monograph
MedlinePlus	a608007
Pregnancy category	US: B (No risk in non-human studies)
Routes of administration	By mouth, nasal, tracheal, rectal
ATC code	A07EA06 (WHO) D07AC09 (WHO), R01AD05 (WHO), R03BA02 (WHO)
Legal status
Legal status	AU: S2 (Pharmacy only) CA: ℞-only UK: POM (Prescription only) US: OTC and Rx-only
Pharmacokinetic data
Bioavailability	10-20% (first pass effect)
Protein binding	85-90%
Metabolism	Hepatic CYP3A4
Biological half-life	2.0-3.6 hours
Excretion	Urine, feces
Identifiers
IUPAC name 16,17-(butylidenebis(oxy))-11,21-dihydroxy-, (11-β,16-α)-pregna-1,4-diene-3,20-dione
Synonyms	11β,21-Dihydroxy-16α,17α-(butylidenebis(oxy))pregna-1,4-diene-3,20-dione
CAS Number	51333-22-3 Y
PubChem CID	40000
DrugBank	DB01222 Y
ChemSpider	4444479 N
UNII	Q3OKS62Q6X
KEGG	D00246 Y
ChEMBL	CHEMBL1370 N
ECHA InfoCard	100.051.927
Chemical and physical data
Formula	C25H34O6
Molar mass	430.534 g/mol
3D model (JSmol)	Interactive image
SMILES CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C
InChI InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1 N Key:VOVIALXJUBGFJZ-KWVAZRHASA N
NY (what is this?)

Budesonide (BUD), sold under the brand name Pulmicort among others, is a medication of the corticosteroid type. It is available as an inhaler, pill, nasal spray, and rectal forms. The inhaled form is used in the long-term management of asthma and chronic obstructive pulmonary disease (COPD). The nasal spray is used for allergic rhinitis and nasal polyps. The pills in a delayed release form and rectal forms may be used for inflammatory bowel disease including Crohn's disease, ulcerative colitis and microscopic colitis.

Common side effects with the inhaled form include respiratory infections, cough, and headaches. Common side effects with the pills include feeling tired, vomiting, and joint pains. Serious side effects include an increased risk of infection, loss of bone strength, and cataracts. Long-term use of the pill form may cause adrenal insufficiency. Stopping the pills suddenly following long-term use may therefore be dangerous. The inhaled form is generally safe in pregnancy. Budesonide is mainly acting as a glucocorticoid.

Budesonide was initially patented in 1973. Commercial use as an asthma medication began in 1981. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. Some forms are available as a generic medication. The wholesale price in the developing world for an inhaler containing 200 doses is about 5 to 7 USD as of 2014. As of 2015 the cost for a typical month of medication in the United States is 100 to 200 USD.